Ipca Laboratories Q3 net profit up 10

The total income during the third quarter increased by 17.67 per cent to Rs 466.71 crore from Rs 396.61 crore in the year-ago period,it added.

The board of the company recommended the second interim dividend of 50 per cent,which is Re 1 per share,for 2010-11.

The total revenue from formulations business stood at Rs 344.63 crore during the October-December quarter as against Rs 284.66 crore in the same period of 2009,up 21.07 per cent.

The total revenue from active pharmaceutical ingredients business of the firm in the three-month period also surged by 8.70 per cent to Rs 118.72 crore from Rs 109.22 crore.

However,reacting to the results,the shares of the company were trading 3.84 per cent down at Rs 309 apiece during late-afternoon on the BSE.